Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

Investors who've been looking for problems at Intellia Therapeutics have, during the past year, had an easy time finding them. A tendency to misinterpret helped. Investors complained about test ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Q1 2025 Management View CEO John Leonard emphasized that Intellia has made significant progress early in 2025, achieving two key milestones: dosing the first patient in Phase 3 studies for hereditary ...

Intellia Therapeutics NTLA incurred a loss of $1.10 per share (including one-time expenses of change in fair value of investments) in the first quarter of 2025, which was narrower than the Zacks ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Intellia Therapeutics, Inc. announced key operational and financial updates for the first quarter of 2025, highlighting significant progress in its clinical trials. The company is on track to ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.